Background and Purpose-According to the European license, alteplase can be given no sooner than 3 months after previous stroke. However, it is not known whether past history of stroke influences the effect of treatment. Our aim was to evaluate safety and functional outcome after intravenous thrombolysis administered in everyday practice to patients with previous stroke ≤3 months compared with those with first-ever stroke. Methods-We analyzed consecutive cases treated with alteplase between October 2003 and July 2014 contributed to the Safe Implementation of Thrombolysis for Stroke-Eastern Europe registry from 12 countries. Odds ratios were calculated using unadjusted and adjusted logistic regression. Results-Of 13 007 patients, 11 221 (86%) had no history of stroke and 249 (2%) experienced previous stroke ≤3 months before admission. Patients with previous stroke ≤3 months had a higher proportion of hypertension and hyperlipidemia. There were no significant differences in outcome, including symptomatic intracerebral hemorrhage according to European Cooperative Acute Stroke Study (unadjusted odds ratio 1.27, 95% confidence interval: 0.74-2.15), and being alive and independent at 3 months (odds ratio 0.81, 95% confidence interval: 0.61-1.09). Conclusions-Patients currently treated with alteplase, despite a history of previous stroke ≤3 months, do not seem to achieve worse outcome than those with first-ever stroke. Although careful patient selection was probably of major importance, our findings provide reassurance that this group of patients may safely benefit from thrombolysis and should not be arbitrarily excluded as a whole. Further studies are needed to identify the shortest safe time lapse from the previous event to treatment with alteplase.
I
ntravenous thrombolysis with recombinant tissue-type plasminogen activator (r-tPA, alteplase) has become the standard of evidence-based stroke care. 1, 2 Its increasing use over the years allowed to accumulate a considerable amount of data supporting off-label treatment in particular situations, [3] [4] [5] [6] [7] [8] [9] [10] [11] including patients with previous stroke or preexisting
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disability. 12, 13 Although European and American guidelines do not list positive history of stroke as a contraindication for thrombolysis, 1,2 the European labeling of alteplase states that any patient who experienced a stroke within the preceding 3 months should be excluded from treatment. 3 Outcome of recurrent strokes is known to be less favorable compared with the first-ever ischemic event, [14] [15] [16] [17] [18] [19] and the amount of evidence directly supporting use of r-tPA for early recurrent strokes is limited. 20 Therefore, many physicians may prefer to arbitrarily refrain from the treatment in this group of patients.
The aim of our study was to investigate what proportion of patients treated with r-tPA in everyday practice had previous stroke within 3 months and whether those patients were more likely to experience hemorrhagic complications or achieve worse outcome compared with those with first-ever stroke.
Methods
This is a retrospective analysis of consecutive patients treated on a regular basis with intravenous thrombolysis between October 2003 and July 2014 whose data were contributed to the Safe Implementation of Treatments in Stroke-Eastern Europe (SITS-EAST) registry.
SITS-EAST uses the SITS International Registry of Thrombolysis in Stroke platform for prospective collection of data on implementation of evidence-based acute stroke care in Central and Eastern Europe. 21 Briefly, SITS was a prospective, multicenter international, academic-driven, monitoring study designed to confirm safety and effectiveness of intravenous thrombolysis in clinical practice. 3, 22 Many Central and Eastern European stroke centers have been joining the registry since the beginning of SITS in 2003. The registry has been approved by local Ethics Committees of each participating country. The current analysis is based on data provided by 158 centers from 12 countries (Figure 1 ).
Patients were considered eligible for the analysis if data about previous stroke and at least 24-hour outcome were eneterd to the registry. No additional exclusion criteria were imposed. Patients were divided into 2 nonoverlaping groups: (1) those with previous stroke ≤3 months before admission and (2) those with first-ever stroke. Previous events were considered strokes only if symptomatic. Silent brain infarcts seen on pretreatment imaging were not considered relevant. Patients were classified as having total anterior circulation infarcts, partial anterior circulation infarcts, posterior circulation infarcts, or lacunar infarcts according to the Oxfordshire Community Stroke Project classification system. 23 Primary outcome measures were (1) occurrence of symptomatic intracranial hemorrhage (sICH) according to European Cooperative Acute Stroke Study (ECASS) II definition (ie, any intracranial hemorrhage combined with National Institutes of Health Stroke Scale [NIHSS] score worsening of at least 4 points or leading to death within 7 days) 24 ; (2) good outcome at 3 months (defined as modified Rankin Scale score of 0-2, meaning alive and independent); and (3) significant neurological improvement at day 7 (defined as improvement of at least 4 points on the NIHSS from baseline or achieving the NIHSS score of 0). Secondary outcome measures included (1) significant neurological improvement at 24 hours (defined as improvement of at least 4 points on the NIHSS from baseline or achieving the NIHSS score of 0); (2) death at 24 hours; (3) death at day 7; and (4) death at 3 months.
The definition of sICH according to ECASS II was chosen because it combines high inter-rater agreement 25 with high predictive value for the worst outcome after thrombolysis. 26 However, we also assessed the occurrence of sICH according to SITS definition (ie, local or remote parenchymal hemorrhage type 2 combined with NIHSS score worsening of at least 4 points or leading to death within 22-36 hours).
22

Statistical Analysis
Categorical variables were presented as number of valid observations with ratio. Proportions were calculated with exclusion of unknown values from the denominator. Because of non-normal distribution, continuous variables were presented as a median with interquartile range.
Patients with a history of previous stroke ≤3 months were compared with those with first-ever stroke using χ 2 test or Mann-Whitney U test, as appropriate. If the expected value in at least one cell of a 2×2 contingency table was <5, Yates correction was applied. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence interval for each outcome measure. Multivariable analyses were arbitrarily adjusted for age, sex, hypertension, atrial fibrillation, congestive heart failure, diabetes mellitus, prestroke disability, and baseline NIHSS score. Additional adjustments were planned for all variables that showed significant difference between investigated group and the reference group. Sensitivity analysis included calculation of odds for selected outcome measures (sICH according to ECASS II definition, modified Rankin Scale score 0-2 at 3 months, and death at 3 months) in subgroups stratified according to prestroke level of disability and baseline neurological deficit. P values of <0.05 were considered statistically significant.
Calculations were performed using STATISTICA 10.0 software package (Stat Soft Inc., Tulsa, 2011).
Results
Of 13 007 patients treated with intravenous thrombolysis, 11 221 (86%) had no history of stroke, 249 (2%) experienced previous stroke ≤3 months before admission, and 1537 (12%) had a history of stroke >3 months before admission. Those proportions were not uniform across SITS-EAST contributing states, as shown in Figure 1 .
Patients with a history of stroke ≤3 months before admission were more frequently burdened with hypertension and hyperlipidemia compared with patients treated with r-tPA for first-ever stroke. They also showed a higher level of preexisting disability, higher proportion of former smokers, as well as more frequent use of antiplatelets and statins (Table 1) .
There were no significant differences in stroke severity, stroke logistics, occurrence of sICH, significant neurological improvement, short-term mortality, and 3-month outcome between patients with first-ever stroke and patients with previous stroke ≤3 months (Table 2 and Figure 2 ). Unadjusted logistic regression suggested that previous stroke ≤3 months before thrombolysis might tend to increase odds for death within 24 hours after treatment (OR 2.21, 95% confidence interval: 0.96-5.06) compared with first-ever stroke (Table 3) . However, this association was not confirmed after adjustment for age, sex, hypertension, atrial fibrillation, congestive heart failure, hyperlipidemia, prestroke disability, prestroke use of antiplatelets, baseline blood glucose, baseline NIHSS score, and administration of intravenous antihypertensives before thrombolysis (OR 1.62, 95% confidence interval: 0.54-4.83). For the full multivariable model, see Table I in the online-only Data Supplement.
Sensitivity analysis in subgroups of patients stratified according to their prestroke level of disability and baseline neurological deficit did not reveal any new associations (Tables II and III in 
Discussion
This is the largest to date multicenter registry-based study that directly investigates the effect of intravenous thrombolysis for recurrent stroke within 3 months from the previous event in everyday practice. According to the literature, recurrent strokes may account for 11% to 33% of all ischemic stro 
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kes. 12, [14] [15] [16] 18, 27 This proportion reaches 13% to 20% 9,10,12,22,24 in patients treated with r-tPA. There are also several case reports of patients who underwent successful systemic thrombolysis for early recurrent strokes. 20, [28] [29] [30] [31] [32] In our cohort, representative of real-life stroke care in Central and Eastern Europe, only 2% of patients treated with r-tPA had previous stroke ≤3 months, which is in line with other studies. 4, [9] [10] [11] 28 Therefore, our findings indirectly confirm that patients with previous stroke constitute potentially large and undertreated group. According to our data, patients with a history of previous stroke ≤3 months were more burdened with vascular risk factors and had worse prestroke functional status compared with those with first-ever stroke, which is partially consistent with observations in unselected stroke cases. 33 In a Swiss cohort, reported by Heldner et al, median time for previous stroke in patients treated ≤3 months was 46 days. 28 Therefore, our findings may also mean that patients who were treated ≤3 months from the previous stroke have already entered chronic or at least subacute stage.
A history of previous stroke is generally considered to increase mortality [14] [15] [16] and be associated with less favorable outcome [17] [18] [19] after recurrent stroke. However, studies on thrombolysis suggest that the effect of r-tPA may not be significantly diminished by a positive history of stroke, 12 silent brain infarcts on baseline CT scan, 34 or a history of ipsilateral transient ischemic attack. 35 Our data show that previous stroke ≤3 months does not independently predict sICH, mortality, or poor functional outcome 3 months after thrombolysis. Although the study is not a randomized trial, it clearly indicates that patients with early recurrence may benefit from thrombolysis and provides an important argument for not withholding the treatment in everyday clinical practice. It is also in line with 2 analyses of general off-label r-tPA use that found no associations with sICH and mortality, and poor outcomes 10, 11 and in several case reports. 20, [29] [30] [31] 36 However, not all previous studies are confirmatory. A registry-based analysis of data from Poland suggested that previous stroke ≤3 months may increase the 3-month risk of death (OR 3.48, P=0.058) and poor outcome (OR 4.07, P=0.055). 9 That study was designed to address off-label thrombolysis as a whole and included only 14 patients treated ≤3 months from the previous stroke. Unfavorable results in terms of 3-month mortality (41% versus 23%) and favorable outcome (29% versus 49%) were also brought by Heldner et al who analyzed a cohort of patients from a single stroke center that excels in thrombectomy (performed in over 50% of all treated cases). 28 Because of disproportionate number of patients (17 versus 1200), authors refrained from statistical comparisons. They also reported that, despite similar NIHSS scores, over 40% of patients with previous stroke ≤3 months had basilar artery occlusion. Therefore, their results may be difficult to extrapolate to population treated mostly with r-tPA.
Study Limitations
Our study has limitations. It is based on data contributed to the registry from multiple centers on a voluntary basis. Therefore, it is not possible to determine how many patients and because 
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of what reasons were not reported or why there are missing values in particular variables. Time from the previous stroke is recorded in the registry as a nominal variable (≤3 month or >3 months), which does not allow quantitative analyzes or identifying patients with ultraearly recurrence. There is also no data about subtype of previous stroke, as well as presence, size, and location of old infarcts. A selection bias may have been also introduced because definitely not all patients who had previous stroke ≤3 months were actually treated with r-tPA, even if otherwise they were fully eligible for thrombolysis. We made efforts to adjust for all important confounding variables. However, it does not guarantee to fully compensate for the bias caused by baseline imbalances and disproportion in number of patients from particular groups. Because of limited number of cases with valid information about prestroke statin therapy, this variable was not included in adjusted logistic regression.
Conclusions
Almost 1 in 50 patients treated with intravenous thrombolysis in Central and Eastern Europe has a history of stroke within 3 months before admission. Despite higher burden with vascular risk factors, those patients seem not to be at increased risk of sICH or poor outcome compared with patients treated for the first-ever stroke. Given the limitations of the current study, our findings provide reassurance that it is not justified to use the 3-month time mark alone to arbitrarily exclude patients with a history of stroke who are otherwise eligible for the treatment. The shortest safe time lapse from the previous event is yet to be determined. Final conclusions need to be based on analyses of randomized data and probably account for the size of recent infarct. Until then, patients with early stroke recurrence should be approached on an individual basis.
Appendix
List of SITS-EAST participating countries with national coordinators: Czech Republic (Robert Mikulik), Poland (Anna Czlonkowska), Slovakia (Zuzana Gdovinova, previously Miroslav Brozman), Hungary (Laszlo Csiba), Estonia (Janika Kõrv), Slovenia (Viktor Svigelj), Croatia (Vanja Bašic-Kes, previously Vida Demarin), Lithuania (Dalius Jatuzis and Alexandras Vilionskis), Turkey (Yakup Krespi), Russia (Nikolay Shamalov), Bulgaria (Silva Andonova). CI indicates confidence interval; ECASS, European Cooperative Acute Stroke Study; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage; and significant improvement, defined as improvement of at least 4 points on the NIHSS from baseline or achieving an NIHSS score of 0.
Sources of Funding
*Adjusted for age, sex, hypertension, atrial fibrillation, congestive heart failure, hyperlipidemia, prestroke disability, prestroke use of antiplatelets, baseline blood glucose, baseline NIHSS score, and administration of intravenous antihypertensives before thrombolysis. 
Intravenous Thrombolysis for Stroke Recurring within 3 Months from the Previous Event
Online only Data Supplement Analysis in subgroups according to prestroke disability is adjusted for age, sex, hypertension, atrial fibrillation, congestive heart failure, hyperlipidemia, prestroke use of antiplatelets, baseline blood glucose, baseline NIHSS score and administration of intravenous antihypertensives before thrombolysis.
Analysis in subgroups according to baseline neurological deficit is adjusted for age, sex, hypertension, atrial fibrillation, congestive heart failure, hyperlipidemia, prestroke disability, prestroke use of antiplatelets, baseline blood glucose and administration of intravenous antihypertensives before thrombolysis.
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*Adjusted for age, sex, hypertension, atrial fibrillation, congestive heart failure, hyperlipidemia, prestroke disability, prestroke use of antiplatelets, baseline blood glucose, baseline NIHSS score, and administration of intravenous antihypertensives before thrombolysis.
